Quick Answer
Edwards Lifesciences Corp reported Net Income Loss of $1.07 billion for the year ending 2025.
- Edwards Lifesciences Corp showed a decrease of -74.3% in Net Income Loss from 2024 to 2025.
- This data is from Edwards Lifesciences Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $406.40 million | Q3 2022: $343.50 million | Q1 2023: $340.50 million | Q2 2023: $307.10 million | Q3 2023: $384.90 million | Q4 2023: $369.90 million | Q1 2024: $351.90 million | Q2 2024: $366.30 million | Q3 2024: $3.07 billion | Q4 2024: $385.60 million | Q1 2025: $358.00 million | Q2 2025: $333.20 million | Q3 2025: $291.10 million.
- Over the full 5 years of available data (2021 to 2025), Edwards Lifesciences Corp's Net Income Loss has declined by 28.6%.
- Historical annual values: Fiscal year 2025: $1.07 billion | Fiscal year 2024: $4.17 billion | Fiscal year 2023: $1.40 billion | Fiscal year 2022: $1.52 billion | Fiscal year 2021: $1.50 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: